Maren S Fragala1, Thuy-Tien L Dam2, Vanessa Barber3, James O Judge3, Stephanie A Studenski4, Peggy M Cawthon5, Robert R McLean6, Tamara B Harris4, Luigi Ferrucci4, Jack M Guralnik7, Douglas P Kiel6, Stephen B Kritchevsky8, Michelle D Shardell7, Maria T Vassileva9, Anne M Kenny10. 1. University of Central Florida, Orlando. 2. Columbia University College of Physicians and Surgeons, New York. 3. University of Connecticut Health Center, Farmington. 4. National Institute of Aging, National Institutes of Health, Bethesda, Maryland. 5. California Pacific Medical Center Research Institute, San Francisco. 6. Hebrew Senior Life Institute for Aging Research, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. 7. University of Maryland School of Medicine, Baltimore. 8. Wake Forest University School of Medicine, Winston-Salem, North Carolina. 9. Foundation for the National Institutes of Health, Bethesda, Maryland. 10. University of Connecticut Health Center, Farmington. kenny@uchc.edu.
Abstract
BACKGROUND: The Foundation for the National Institutes of Health Sarcopenia Project developed data-driven cut-points for clinically meaningful weakness and low lean body mass. This analysis describes strength and function response to interventions based on these classifications. METHODS: In data from four intervention studies, 378 postmenopausal women with baseline and 6-month data were evaluated for change in grip strength, appendicular lean mass corrected for body mass index, leg strength and power, and short physical performance battery (SPPB). Clinical interventions included hormones, exercise, and nutritional supplementation. Differences in outcomes were evaluated between (i) those with and without weakness and (ii) those with weakness and low lean mass or with one but not the other. We stratified analyses by slowness (walking speed ≤ 0.8 m/s) and by treatment assignment. RESULTS: The women (72±7 years; body mass index of 26±5kg/m(2)) were weak (33%), had low lean mass (14%), or both (6%). Those with weakness increased grip strength, lost less leg power, and gained SPPB score (p < .05) compared with nonweak participants. Stratified analyses were similar for grip strength and SPPB. With lean mass in the analysis, individuals with weakness had larger gains in grip strength and SPPB scores regardless of low lean mass (p < .01). CONCLUSIONS: Older women with clinically meaningful muscle weakness increased grip strength and SPPB, regardless of the presence of low lean mass following treatment with interventions for frailty. Thus, results suggest that muscle weakness, as defined by the Foundation for the National Institutes of Health Sarcopenia Project, appears to be a treatable symptom.
BACKGROUND: The Foundation for the National Institutes of Health Sarcopenia Project developed data-driven cut-points for clinically meaningful weakness and low lean body mass. This analysis describes strength and function response to interventions based on these classifications. METHODS: In data from four intervention studies, 378 postmenopausal women with baseline and 6-month data were evaluated for change in grip strength, appendicular lean mass corrected for body mass index, leg strength and power, and short physical performance battery (SPPB). Clinical interventions included hormones, exercise, and nutritional supplementation. Differences in outcomes were evaluated between (i) those with and without weakness and (ii) those with weakness and low lean mass or with one but not the other. We stratified analyses by slowness (walking speed ≤ 0.8 m/s) and by treatment assignment. RESULTS: The women (72±7 years; body mass index of 26±5kg/m(2)) were weak (33%), had low lean mass (14%), or both (6%). Those with weakness increased grip strength, lost less leg power, and gained SPPB score (p < .05) compared with nonweak participants. Stratified analyses were similar for grip strength and SPPB. With lean mass in the analysis, individuals with weakness had larger gains in grip strength and SPPB scores regardless of low lean mass (p < .01). CONCLUSIONS: Older women with clinically meaningful muscle weakness increased grip strength and SPPB, regardless of the presence of low lean mass following treatment with interventions for frailty. Thus, results suggest that muscle weakness, as defined by the Foundation for the National Institutes of Health Sarcopenia Project, appears to be a treatable symptom.
Authors: Ellen F Binder; Kenneth B Schechtman; Ali A Ehsani; Karen Steger-May; Marybeth Brown; David R Sinacore; Kevin E Yarasheski; John O Holloszy Journal: J Am Geriatr Soc Date: 2002-12 Impact factor: 5.562
Authors: Marjolein Visser; Stephen B Kritchevsky; Bret H Goodpaster; Anne B Newman; Michael Nevitt; Elizabeth Stamm; Tamara B Harris Journal: J Am Geriatr Soc Date: 2002-05 Impact factor: 5.562
Authors: Sari Stenholm; Tamara B Harris; Taina Rantanen; Marjolein Visser; Stephen B Kritchevsky; Luigi Ferrucci Journal: Curr Opin Clin Nutr Metab Care Date: 2008-11 Impact factor: 4.294
Authors: Robert R McLean; Michelle D Shardell; Dawn E Alley; Peggy M Cawthon; Maren S Fragala; Tamara B Harris; Anne M Kenny; Katherine W Peters; Luigi Ferrucci; Jack M Guralnik; Stephen B Kritchevsky; Douglas P Kiel; Maria T Vassileva; Qian-Li Xue; Subashan Perera; Stephanie A Studenski; Thuy-Tien L Dam Journal: J Gerontol A Biol Sci Med Sci Date: 2014-05 Impact factor: 6.053
Authors: Dawn E Alley; Michelle D Shardell; Katherine W Peters; Robert R McLean; Thuy-Tien L Dam; Anne M Kenny; Maren S Fragala; Tamara B Harris; Douglas P Kiel; Jack M Guralnik; Luigi Ferrucci; Stephen B Kritchevsky; Stephanie A Studenski; Maria T Vassileva; Peggy M Cawthon Journal: J Gerontol A Biol Sci Med Sci Date: 2014-05 Impact factor: 6.053
Authors: Kirsten K Ness; Gregory T Armstrong; Mondira Kundu; Carmen L Wilson; Tamara Tchkonia; James L Kirkland Journal: Cancer Date: 2014-12-19 Impact factor: 6.860
Authors: Karl A Rodriguez; Joseph M Valentine; David A Kramer; Jonathan A Gelfond; Deborah M Kristan; Eviatar Nevo; Rochelle Buffenstein Journal: Cell Stress Chaperones Date: 2016-02-19 Impact factor: 3.667
Authors: Jonathan P Singer; Joshua M Diamond; Michaela R Anderson; Patricia P Katz; Ken Covinsky; Michelle Oyster; Tatiana Blue; Allison Soong; Laurel Kalman; Pavan Shrestha; Selim M Arcasoy; John R Greenland; Lori Shah; Jasleen Kukreja; Nancy P Blumenthal; Imaani Easthausen; Jeffrey A Golden; Amika McBurnie; Ed Cantu; Joshua Sonett; Steven Hays; Hilary Robbins; Kashif Raza; Matthew Bacchetta; Rupal J Shah; Frank D'Ovidio; Aida Venado; Jason D Christie; David J Lederer Journal: Am J Transplant Date: 2018-05-14 Impact factor: 8.086
Authors: Marian L Neuhouser; Rebecca P Hunt; Linda Van Horn; James M Shikany; Marcia L Stefanick; Karen C Johnson; Robert Brunner; Brad Cannell; Irene E Hatsu; Lesley F Tinker Journal: Prev Med Date: 2020-08-12 Impact factor: 4.018